BioInformant

Your Global Leader in Stem Cell Market Research

Home » stem cell » Page 2

BioEden Reports 275% Increase in Demand for Dental Stem Cell Storage Service, Extends Reach to Belgium and Holland

By 1 Comment

Dental pulp is the soft living tissue inside a tooth that contains mesenchymal stem cells (MSCs). While MSCs from dental pulp stem cells are only being used only in laboratory settings right now, there are now a handful of forward-thinking companies that offer dental stem cell storage services to preserve the cells for future regenerative use.

The dental pulp storage market is still relatively small, because of the early stage of research concerning the use of dental pulp stem cells in humans. However, it is rapidly expanding on a global basis, with 1-2 new dental storage providers are entering the market every month, based on a trailing 12-month history (January to December, 2015).

BioEden began offering tooth stem cell storage as early as 2006, making it one of the earliest known providers of dental stem cell storage. Over the past decade, the company has continued to be one of the most dominant competitors in this space, controlling an estimated 45% of current market share within the dental stem cell storage market. Click here to learn more about the dental stem cell banking market or to read our recent interview with BioEden’s CEO, Tony Veverka.  [Read more…]

Aussie Stem Cell Company Cynata Therapeutics Signs LOI with apceth GmbH

By Leave a Comment

Global Cooperation: Australia’s Cynata Therapeutics to Partner with Germany’s apceth GmbH & Co. KGCynata Therapeutics, an Australian stem cell company with a powerful mesenchymal stem cell (MSC) manufacturing technology, has signed a Letter of Intent (LOI) with the German giant,apceth GmbH & Co. a company developing genetically engineered, next generation mesenchymal stem cell (MSC) therapeutics.

This is a significant announcement, because apceth GmbH & Co. KG is an extremely well-funded group. Their major shareholders are the Strungmann family, which previously owned Hexal, one of the largest manufacturers of generic pharmaceuticals in Europe. While apceth GmbH & Co. KG is not widely known within the United States, it is a major force within the European Union (EU) biotech market.  [Read more…]

Key Events in the Evolution of iPSC Products that You Need to Know

By Leave a Comment

Developing induced pluripotent stem cell (iPSC) products requires a thorough understanding of the evolution of iPSC research advances. Because the cell type was recently discovered in 2006, the following presents a decade-long timeline of key events in the discovery and evolution of induced pluripotent stem cell products.

The research events below drove forward interest in the use of iPSCs for basic research and clinical applications. These events are the reason that the first clinical trial involving the implantation of iPSCs into humans was initiated in 2013, to assess the capacity of the cell type to treat loss of eyesight due to macular degeneration.

For this reason, stem cell company executives and stem cell industry investors will be better suited to make future decisions about iPSC products if they have a historical understanding of the recent past and the rate at which research advances with the cell type accelerated. [Read more…]

BioInformant's World-Class Clients